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Abstract
Background: Migraine attacks usually occur at any time, in particular either during days off or workdays. Limited
evidence is available on the efficacy of antimigraine drugs in patients whose attacks occur on weekends.
Objective: To evaluate the efficacy of four different triptans in weekend vs. workday migraine attacks through a
pooled analysis of individual data of three randomized, double-blind, crossover studies.
Methods: Subjects with a history of migraine with or without aura were randomized to frovatriptan 2.5 mg or
rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan
12.5 mg (study 3). Each patient was requested to treat up to 3 attacks with each drug during both 3 month periods,
as established by the crossover trial protocol. In this retrospective analysis the migraine attacks occurring on
workdays were differentiated from those occurring on weekends. The efficacy of the drugs during weekends and
workdays was compared.
Results: Of the 346 intention-to-treat population patients, 188 (54%) had migraine attacks also on weekends.
Overall, a total of 569 attacks occurred during weekends and 1,281 during workdays. Proportion of pain-free at 2
hours did not significantly differ between weekend and workday attacks for frovatriptan (26% vs. 27%) as well as for
comparators (34% vs. 32%). Headache relief episodes were also similarly represented between weekend and non-
weekend attacks (frovatriptan: 40% vs. 42% and comparators: 49% vs. 43%, p=NS). Conversely, the relapse rate
within 48 hours for weekend attacks compared to workday attacks was significantly lower with frovatriptan (17% vs.
30%, p<0.05), while this finding was not observed for comparators (weekends 34% vs. workdays 40%, p=NS).
Conclusions: Our study provides the first evidence that frovatriptan represents a particularly favorable option for
treating weekend migraine attacks.
Keywords: Migraine Headache; Frovatriptan; Rizatriptan;
Zolmitriptan; Almotriptan; Weekend Migraine; Relapse.
Introduction
Approximately 30% of patients with a diagnosis of migraine or, less
frequently, tension-type headache, claim to have their attacks mainly
on weekends, particularly in case of migraine without aura [1,2]. It has
been a matter of debate in recent years whether days off represent a
possible trigger for headache, with some studies showing a clear
relationship [3,4] and other surveys failing to confirm this association
[5-7].
Psychological factors seem to play an important role in the
pathophysiology and clinical development of weekend migraine and
some authors in the past have postulated that a psychic tension
component might be superimposed to the vascular component in this
subtype of migraine [8]. Although weekend migraine has been a
poorly investigated condition over the years and specific evidence of
drug efficacy for treatment of this condition is lacking, there is no
reason to doubt that current drug options for migraine treatment can
also be effective for weekend headache.
Selective serotonin 5-HT1B/1D receptor agonists (the triptans) have
been shown to be effective acute migraine drugs, and are currently
recommended as first-line treatment for moderate-to-severe migraine,
or for mild-to-moderate migraine attacks which have not responded to
adequate doses of simple analgesics or non-steroidal anti-
inflammatory drugs [9-12]. In an observational prospective survey
regarding 3415 patients it was found out that more than 5% of all
migraineurs have their attacks mostly on weekends. The subjects with
at least 75% of all their migraine attacks occurring on weekends, with a
frequency ranging from 1 attack every 2 months to 4 attacks per
month, were arbitrarily considered as patients suffering from weekend
migraine. Up to now possible diagnostic criteria for weekend migraine
are lacking and have never been proposed. Anyway, weekend migraine
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was unexpectedly found to be more common in males than in females
(52.6% vs. 47.4%); the attacks were reported to be severe in intensity
and markedly disabling in most cases, responding only to triptans in
over 50% of the subjects [13].
Frovatriptan is the newest addition to the triptan class, developed in
order to provide a compound with a clinical potential for a long
duration of action and a low likelihood of side effects and drug
interactions [14, 15]. Recently, three direct comparative, prospective,
double-blind, randomized, crossover studies have compared the
efficacy and safety of frovatriptan versus other second-generation
triptans, such as rizatriptan [16], zolmitriptan [17] and almotriptan
[18]. The study results showed a similar efficacy of the four triptans in
the early treatment (within 2 hours) of migraine, but a lower rate of
relapse, and thus a better sustained relief, with frovatriptan.
Retrospective analyses of the same studies demonstrated the good
efficacy profile of frovatriptan also in other subtypes of migraine, such
as menstrually related migraine [19-22] and migraine with aura [23].
In this paper we report on the results of a retrospective analysis
performed in patients having migraine attacks also on weekends, who
were enrolled in the three aforementioned head-to-head studies
[16-18].
Methods
Setting and study population
Details on study design have been published elsewhere [16-18].
Briefly, the studies included male or female subjects, aged 18-to-65
years, with a current history of migraine with or without aura,
according to International Headache Society (IHS) criteria [24], and
with at least one, but no more than 6 migraine attacks per month for
the 6 months prior to entering the study. Subjects were recruited in 43
different headache centers in Italy.
Patients could not be enrolled in the study in case of: a)
uncontrolled hypertension; b) ischemic heart disease; c) cardiac
arrhythmias or symptomatic Wolff-Parkinson-White syndrome; d)
previous stroke or cerebral transient ischemic attack; e) severe liver or
renal impairment; f) any other severe or disabling medical condition;
g) history of alcohol or analgesic or psychotropic drug abuse; h)
known hypersensitivity to study drugs; i) previously demonstrated
inadequate response to at least two triptans; j) current use of
propranolol or ergot derivatives as prophylactic agents; k) current use
or use in the previous 2 weeks of MAO-inhibitors; l) use of either
study medication to treat any one of the last three episodes of
migraine; m) other headaches lasting for more than 6 days. Pregnant
and breast-feeding women were excluded as well, while women with
childbearing potential but not using an effective contraceptive method
were submitted to a pregnancy test, if clinically indicated.
Written informed consent was obtained from all patients prior to
their inclusion into the study. The study was approved by the
Independent Institutional Review Boards of the study centers.
Study design
All studies had a randomized, double blind, crossover design. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg [16],
frovatriptan 2.5 mg or zolmitriptan 2.5 mg [17], and frovatriptan 2.5
mg or almotriptan 12.5 mg [18]. Treatment assignment was made
possible through a balanced computer-generated randomized
sequence (1:1), where frovatriptan had to be followed by the
comparator or vice-versa. Randomization was performed by blocks of
4. Blindness was ensured by the overencapsulation technique, i.e. by
inserting study drug tablets in capsules. After treating up to 3 episodes
of migraine in no more than 3 months with the first treatment, the
patients had to switch to the other treatment and were asked to treat a
maximum of three episodes of migraine in no more than 3 months
with the second treatment.
The study included a total of three visits and each patient’s
participation time in the study had not to exceed 6 months from
randomization. Subjects having no migraine episodes during either
first or second observation period were excluded from the study.
During the randomization visit, after signing written informed
consent, subjects provided a detailed general and headache history,
and their medication use was evaluated. A physical and neurological
examination and pregnancy test (if appropriate) were performed.
Blood pressure and heart rate were measured for all subjects. The
degree of migraine-associated disability (MIDAS questionnaire) was
also measured. At the end of the first visit a headache diary showing
characteristics of headache pain and associated symptoms was
delivered together with study medication. Subjects were instructed to
treat up to 3 migraine episodes occurring in no more than 3 months
and to return for the second visit. On this occasion, use of
concomitant medications and possible occurrence of adverse events
(as gathered from the diary) were evaluated, blood pressure and heart
rate were recorded, and a pregnancy test performed, if deemed
necessary. The same procedures were carried out at the end of the
second study treatment period or at the early withdrawal visit, together
with the administration of the patient’s preference questionnaire.
Patients were instructed to take one dose of study medication as
early as possible after the onset of migraine attack. If insufficient relief
had been obtained at 2 hours, patients were allowed to take a second
dose of study medication, with a maximum daily intake of two doses.
In case of insufficient benefit one hour after the intake of the second
dose of the study medication, patients were allowed to take a rescue
medication. Alternate rescue medications could not include triptans or
ergot alkaloids.
Data analysis
In the original studies, analysis was performed on the intention-to-
treat population, including all patients who treated at least one attack
in each treatment period and completed the preference questionnaire.
The study endpoints were established following the IHS Guidelines
[24]. The objectives were: a) the number of pain-free episodes at 2
hours, i.e. absence of pain within 2 hours of the intake of one dose of
study drug and without any rescue medication; b) the number of pain
relief episodes at 2 hours, defined as a decrease in migraine intensity
from severe or moderate to mild or none, after the intake of one study
drug dose; and c) relapse within 48 hours, defined according to the
IHS Guidelines, namely when a patient is pain-free within 2 hours
after treatment and headache of any severity returns within 48 hours,
or requires the use of rescue medication or a second dose of study
drug.
Each outcome measure was compared between workday and
weekend attacks and within each type of triptan therapy. Continuous
variables were summarized by computing average values and standard
deviation (SD), while categorical variables by computing the absolute
value and the frequency (as percentage). Study endpoints were
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compared between weekend and workday attacks by analysis of
variance (ANOVA), in case of continuous variables, and by Chi-
square test, in case of discrete variables. P-value refers to the statistical
significance analyzing between-treatment difference. The level of
statistical significance was kept at <0.05 throughout the whole study.
Results
Baseline demographic and clinical data.
Figure 1 illustrates the patients flow during the study. Out of the
total 346 patients, 188 (54%) of the pooled intention-to-treat
population, reported attacks of migraine without aura occurring also
on weekends: these 188 patients were treated with frovatriptan (100%),
62 (33%) with rizatriptan, 60 (32%) with zolmitriptan and 66 (35%)
with almotriptan, respectively. Table 1 shows main demographic and
clinical characteristics of these patients. Most of the enrolled subjects
were females. No statistically significant differences were observed
between the main study group and the weekend migraine subgroup as
for the clinical features taken into consideration.
Figure 1: Flow diagram of the patients throughout the study
Subjects with
 
weekend migraine
 
(n=188)
Whole study
 
population
 
(n=346)
p-value
Age (years, means ± SD) 38 ± 9 38 ± 10 NS
Females (n, %) 151 (80) 280 (81) NS
Height (cm, means ± SD) 166 ± 8 166 ± 8 NS
Weight (kg, means ± SD) 65±11 64 ± 12 NS
Age at onset of migraine (years, means ± SD) 17±7 17 ± 7 NS
Migraine attack duration >2 days (n, %) 38 (20) 75 (22) NS
MIDAS score (means±SD) 23 ± 15 22 ± 15 NS
No use of triptans in the previous 3 months (n, %) 51 (27) 95 (28) NS
Table 1: Baseline demographic and clinical data of the 188 patients included in the analysis of weekend migraine and of the 346 subjects of the
whole study population. Data are shown as mean (± SD), or absolute (n) and relative frequency (%).
Characteristics of migraine attacks
A total of 1,850 migraine attacks without aura were recorded during
the study periods. Of these attacks, 1,281 (69%) occurred during
workdays and 569 (31%) during weekends. The proportion of
weekend attacks was similar for the four treatment periods: 31% under
frovatriptan, 28% rizatriptan, 31% zolmitriptan and 33% almotriptan,
respectively. As shown in Figure 2 (top panel), when single days were
taken into account, migraine attacks resulted unevenly distributed
throughout the week. In regard to the specific day of the week, the
average number of attacks was slightly, but significantly (p<0.0001),
greater during the weekends (285 ± 45 attacks) than during the
workdays (256 ± 37 attacks). The intensity of attacks, recorded
immediately before drug intake, was independent of the day of
occurrence throughout the week (Figure 2, bottom panel), in
particular on weekends compared to workdays (2.0 ± 0.7 vs. 2.0 ± 0.6,
p=NS).
Figure 2: Percentage (%) of attacks during each single day of the
week (top panel) and average (± SD) intensity of baseline untreated
attack (bottom panel) in the 188 subjects with weekend migraine.
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Treatment efficacy of migraine attacks
In the intention-to-treat population, proportions of pain-free and
pain relief episodes at 2 hours were not significantly different between
weekend and workday migraine attacks, for any of the study drugs
(Figure 3). The proportion of pain-free at 2 hours was 26% during
weekends and 27% during workdays under frovatriptan, and 34% and
32% under the pooled together comparators, respectively. Pain relief
episodes were also similarly distributed between weekend and non-
weekend attacks for both frovatriptan (40% vs. 42%) and comparators
(49% vs. 43%).
Figure 3: Proportion (%) of pain free at 2 hours, pain relief at 2
hours and relapse at 48 hours during workday (open bar) and
weekend attacks (grey bar) in the 188 subjects with weekend
migraine. Data are separately shown for each of the four triptans
tested in the study. The p-value refers to statistical significance of
the between-period difference.
Conversely, proportion of recurring episodes (relapses) was
significantly lower (p<0.05) under frovatriptan during weekend rather
than during workday attacks (17% vs. 30%), whereas no difference
between the two periods was observed for the attacks treated with the
other pooled together triptans (weekends 34% vs. workdays 40%), as
shown in Figure 3.
Discussion
In our pooled analysis of three double-blind, randomized, crossover
studies, no significant difference was found between weekend and
workday attacks treated with frovatriptan and comparators
(rizatriptan, zolmitriptan and almotriptan) in terms of pain-free and
pain relief rates at 2 hours. When headache relapse within 48 hours
was considered, frovatriptan showed a more sustained relieving action
compared to the other triptans. As a matter of fact, the relapse rate at
48 hours for attacks occurring on weekends was significantly lower
with frovatriptan. This finding is not surprising, since frovatriptan is
known to have a long half-life, thus possibly determining a lower
proportion of headache recurrence [25-27]. Moreover, this result
could be explained by the very early intake of medication, during
migraine premonitory phase, due to the consistent predictability of
attacks [13]. Interestingly, these data found in the subgroup of subjects
treating migraine attacks occurring on weekends, are in line with those
observed in the main study population [28] and in the subgroups of
women with menstrual migraine [22] and with oral contraceptive-
induced menstrual migraine [29].
Our retrospective analysis of the three double-blind, randomized
studies represents the first study assessing the efficacy of different
triptans in the acute treatment of weekend migraine. Actually there are
other studies which specifically evaluated the effectiveness of the
treatment of weekend migraine with triptans. In an open-label, non-
randomized study 28 subjects suffering from weekend migraine were
prophylactically treated for two consecutive weekends with
frovatriptan 2.5 mg, followed by two other consecutive weekends with
naproxen 500 mg [30]. Both medications were taken in a single dose
on Saturday and Sunday morning. Active therapy was preceded by two
weekends during which no treatment was administered. The treatment
with frovatriptan was associated with a lower migraine intensity,
particularly in the subgroup of patients not taking any rescue
medication. In addition, the use of rescue medication was lower under
frovatriptan than naproxen. The second study assessed the short-term
efficacy of rizatriptan 5 mg vs. placebo in 476 adolescents with
migraine [31]. In this single-attack study, patients were instructed to
use the study medication only on non-school days. Even if fewer
patients than expected (30%) treated their migraine attacks on
weekends, the proportion of pain relief at 2 hours was significantly
higher in the rizatriptan group than in the placebo group (74% vs.
58%). In an open-label, prospective, observational study which
included 200 patients with weekend migraine, 99 subjects were treated
with a short-term prophylaxis either with magnesium (63 cases) or
with frovatriptan 2.5 mg (36 cases). Patients with weekend migraine
were arbitrarily defined as subjects with at least 75% of all their
migraine attacks occurring on weekends, with a frequency ranging
from 1 attack every 2 months to 4 attacks per month. Five doses were
administered, one on Friday evening and on Sunday morning, and two
(one in the morning and one in the evening) on Saturday. The
endpoint was the reduction by at least 50% in headache hours. This
decrease was noted in 9.5% of patients taking magnesium and in 63.9%
of subjects treated with frovatriptan 2.5 mg [13].
Our study provides some additional matter of discussion. First, we
did not find a particular difference in migraine intensity between
weekend and workday attacks, which confirms previous evidence [8].
Second, although the study did not specifically enroll weekend
migraineurs, the average number of migraine attacks was significantly
higher during days off rather than during workdays, confirming the
possible triggering role of relaxation after stress to provoke migraine
attacks [2,8]. Third, we assert that weekend migraine cannot be
considered as a distinct subtype of migraine. Weekends, as well as
stress, some foods and beverages, sleep (too much or too little),
weather changes and several other factors just act as triggers.
Interestingly, a significant number of migraine patients report their
attacks to occur mostly on weekends, as if they were susceptible almost
only to this factor. Nonetheless, weekend migraine does not seem to
occur so consistently as menstrually related migraine, the only subtype
of migraine included in the International Classification of Headache
Disorders-3 beta Appendix. Therefore, we did not propose any
diagnostic criteria for weekend migraine, since we believe that it
cannot be considered as a possible distinct entity, as likely menstrually
related migraine. We deem that more attention should be given to
weekend migraine in future studies, in order to establish a strict and
clinically acceptable definition, with clear diagnostic elements, suitable
for clinical practice e for possible future investigations on this type of
migraine. Fourth, previous studies have shown that, due to its
pharmacological properties, frovatriptan is particularly effective in the
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short-term prophylactic therapy of some types of migraine, like
menstrually related migraine [32-34] and long-lasting migraine
attacks, usually with a high relapse rate [35]. In 2012 a Task Force of
the American Academy of Neurology and the American Headache
Society published the revised clinical practice guidelines for episodic
migraine prevention in adults. Frovatriptan was the only triptan
included in these guidelines, notably in the level A medications group,
labelled with the specific indication for short-term prophylaxis of
menstrually related migraine, based on two class I studies [36].
Given that weekend migraine is also characterized by consistent
triggering factors and a predictable occurrence, a possible benefit of
frovatriptan as prophylactic agent as well as symptomatic medication
of this subtype of migraine should be explored in the future.
Some weaknesses of our study deserve to be discussed. First, we
performed a retrospective analysis on a subgroup of patients, who
were not originally selected as specifically weekend migraine sufferers.
Although we included a large number of patients (n=188) and attacks
(n=569), a post-hoc power analysis, run in this subgroup of subjects,
revealed differences in statistical power between frovatriptan (98%)
and the comparators pooled together (70%). Albeit the sample size
might have been inadequate, our results appear to be clinically
relevant, because no such prospective studies comparing the efficacy of
different triptans in weekend migraineurs have yet been carried out. In
addition, baseline characteristics of our subgroup of migraineurs were
similar to those of the main study population. We also limited as much
as possible the number of endpoints and outcome measures, and the
study assumptions, since the evaluation of this subgroup of migraine
patients can be considered as a benchmark for subsequent future
clinical trials to confirm or refute our findings. Finally, the proportion
of subjects having migraine attacks on weekends (54%) was slightly
higher than that reported in the literature (20-30%) (1,4). Thus far,
this might be probably related to the bias in the selection of patients
and to the retrospective nature of our analysis.
In conclusion, the results of our systematic analysis of individual
data of three double-blind, randomized, direct, comparative studies
provide strong evidence that triptans are effective also in treating
weekend migraine attacks. Among the different triptans, frovatriptan
seems to offer the advantage of a lower risk of relapse and therefore a
more sustained effect during attacks occurring on days off from work.
Moreover, frovatriptan can be used as a symptomatic medication, but
also prophylactically for a short-term preventive treatment. We
acknowledge that further large double-blind, randomized, studies are
needed and warranted to explore the possible acute and prophylactic
efficacy of frovatriptan in patients specifically suffering from weekend
migraine.
Acknowledgements
The present study was supported by Istituto Lusofarmaco d’Italia.
Conflict of Interest
All authors have occasionally served as scientific consultants for
manufacturers of frovatriptan, rizatriptan, zolmitriptan or
almotriptan. Deborha Pezzola and Dario Zava are employees of
Istituto Lusofarmaco d’Italia S.p.A.
References
1. Couturier EG, Hering R, Steiner TJ (1992) Weekend attacks in migraine
patients: caused by caffeine withdrawal? Cephalalgia 12: 99-100.
2. Torelli P, Cologno D, Manzoni GC (1999) Weekend headache: a
retrospective study in migraine without aura and episodic tension-type
headache. Headache 39: 11-20.
3. Cugini P, Romit A, Di Palma L, Giacovazzo M (1990) Common migraine
as a weekly and seasonal headache. Chronobiol Int 7: 467-469.
4. Torelli P, Cologno D, Manzoni GC (1999) Weekend headache: a possible
role of work and life-style. Headache 39: 398-408.
5. Wöber C, Brannath W, Schmidt K, Kapitan M, Rudel E, et al. (2007)
Prospective analysis of factors related to migraine attacks: the PAMINA
study. Cephalalgia 27: 304-314.
6. Morrison DP (1990) Occupational stress in migraine--is weekend
headache a myth or reality? Cephalalgia 10: 189-193.
7. Alstadhaug KB, Salvesen R, Bekkelund S (2007) Weekend migraine.
Cephalalgia 27: 343-346.
8. Nattero G, De Lorenzo C, Biale L, Allais G, Torre E, et al. (1989)
Psychological aspects of weekend headache sufferers in comparison with
migraine patients. Headache 29: 93-99.
9. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, et al. (2009) EFNS
guideline on the drug treatment of migraine--revised report of an EFNS
task force. Eur J Neurol 16: 968-981.
10. Loder E (2010) Triptan therapy in migraine. N Engl J Med 363: 63-70.
11. Johnston MM, Rapoport AM (2010) Triptans for the management of
migraine. Drugs 70: 1505-1518.
12. Belvís R, Pagonabarraga J, Kulisevsky J (2009) Individual triptan
selection in migraine attack therapy. Recent Pat CNS Drug Discov 4:
70-81.
13. Evers S, Lisotto C (2013) An algorithm of migraine treatment. European
Neurological Review 8: 149-152.
14. Balbisi EA (2004) Frovatriptan succinate, a 5-HT1B/1D receptor agonist
for migraine. Int J Clin Pract 58: 695-705.
15. Sanford M (2012) Frovatriptan: a review of its use in the acute treatment
of migraine. CNS Drugs 26: 791-811.
16. Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD et al. (2011). A
double-blind, randomized, multicenter, Italian study of frovatriptan
versus rizatriptan for the acute treatment of migraine. J Headache Pain
12: 219-226.
17. Tullo V, Allais G, Ferrari MD, Curone M, Mea E, et al. (2010)
Frovatriptan versus zolmitriptan for the acute treatment of migraine: a
double-blind, randomized, multicenter, Italian study. Neurol Sci 31
Suppl 1: S51-54.
18. Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D et
al. (2011). A double-blind, randomized, multicenter, Italian study of
frovatriptan versus almotriptan for the acute treatment of migraine. J
Headache Pain 12: 361-368.
19. Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD et al. (2011).
Efficacy of frovatriptan in the acute treatment of menstrually related
migraine: analysis of a double-blind, randomized, cross-over,
multicenter, Italian, comparative study versus rizatriptan. J Headache
Pain 12: 609-615.
20. Allais G, Tullo V, Benedetto C, Zava D, Omboni S et al. (2011) Efficacy of
frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, multicenter, Italian, comparative
study versus zolmitriptan. Neurol Sci 32: S99-S104.
21. Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D et
al. (2012) Frovatriptan versus almotriptan for acute treatment of
menstrual migraine: analysis of a double-blind, randomized, cross-over,
multicenter, Italian, comparative study. J Headache Pain 13: 401-406.
22. Allais G, Tullo V, Omboni S, Benedetto C, Sances G et al. (2012) Efficacy
of frovatriptan versus other triptans in the acute treatment of menstrual
migraine: pooled analysis of three double-blind, randomized, crossover,
multicenter studies. Neurol Sci 33: S65-S69.
Citation: Lisotto C, Savi L, Pinessi L, Guidotti M, Omboni S, et al. (2014) Efficacy of Frovatriptan vs. Other Triptans in Weekend Migraine: Pooled
Analysis of Three Double-Blind, Randomized, Crossover, Multicenter Studies. Brain Disord Ther 3: 128. doi:10.4172/2168-975X.
1000128
Page 5 of 6
Brain Disord Ther
ISSN:2168-975X BDT, an open access journal Volume 3 • Issue 3 • 1000128
23. Tullo V, Allais G, Curone M, Ferrari MD, Omboni S et al. (2012)
Frovatriptan versus zolmitriptan for the acute treatment of migraine with
aura: a subgroup analysis of a double-blind, randomized, multicenter,
Italian study. Neurol Sci 33: S61-S64.
24. Headache Classification Subcommittee of the International Headache
Society. The International Classification of Headache Disorders, 2nd ed.
Cephalalgia (2004) 24: 9-160.
25. Kelman L (2008) Review of frovatriptan in the treatment of migraine.
Neuropsychiatr Dis Treat 4: 49-54.
26. Géraud G, Keywood C, Senard JM (2003) Migraine headache recurrence:
relationship to clinical, pharmacological, and pharmacokinetic properties
of triptans. Headache 43: 376-388.
27. Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, et al. (2011)
Pharmacokinetic evaluation of frovatriptan. Expert Opin Drug Metab
Toxicol 7: 1449-1458.
28. Cortelli P, Allais G, Tullo V, Benedetto C, Zava D et al. (2011)
Frovatriptan versus other triptans in the acute treatment of migraine:
pooled analysis of three double-blind, randomized, cross-over,
multicenter, Italian studies. Neurol Sci 32: S95-S98.
29. Allais G, Tullo V, Omboni S, Pezzola D, Zava D et al. (2013) Frovatriptan
vs. other triptans for the acute treatment of oral contraceptive-induced
menstrual migraine: pooled analysis of three double-blind, randomized,
crossover, multicenter studies. Neurol Sci 34: S83-S86.
30. Guidotti M, Barrilà C, Leva S, De Piazza C, Omboni S (2013)
Symptomatic or prophylactic treatment of weekend migraine: an open-
label, nonrandomized, comparison study of frovatriptan versus naproxen
sodium versus no therapy. Neuropsychiatr Dis Treat 9: 81-85.
31. Visser WH, Winner P, Strohmaier K, Klipfel M, Peng Y et al. (2004)
Rizatriptan Protocol 059 and 061 Study Groups. Rizatriptan 5 mg for the
acute treatment of migraine in adolescents: results from a double-blind,
single-attack study and two open-label, multiple-attack studies. Headache
44: 891-899.
32. Balbisi EA (2006) Frovatriptan: a review of pharmacology,
pharmacokinetics and clinical potential in the treatment of menstrual
migraine. Ther Clin Risk Manag 2: 303-308.
33. Brandes JL, Poole Ac, Kallela M, Schreiber CP, MacGregor EA, et al.
(2009) Short-term frovatriptan for the prevention of difficult-to-treat
menstrual migraine attacks. Cephalalgia 29: 1133-1148.
34. Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC (2009)
Scheduled short-term prevention with frovatriptan for migraine
occurring exclusively in association with menstruation. Headache 49:
1283-1297.
35. Kelman L, Harper SQ, Hu X, Campbell JC (2010) Treatment response
and tolerability of frovatriptan in patients reporting short- or long-
duration migraines at baseline. Curr Med Res Opin 26: 2097-2104.
36. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C et al. (2012)
Evidence-based guideline update: Pharmacologic treatment for episodic
migraine prevention in adults. Report of the Quality Standards
Subcommittee of the American Academy of Neurology and the
American Headache Society. Neurology 78: 1337-1345.
 
Citation: Lisotto C, Savi L, Pinessi L, Guidotti M, Omboni S, et al. (2014) Efficacy of Frovatriptan vs. Other Triptans in Weekend Migraine: Pooled
Analysis of Three Double-Blind, Randomized, Crossover, Multicenter Studies. Brain Disord Ther 3: 128. doi:10.4172/2168-975X.
1000128
Page 6 of 6
Brain Disord Ther
ISSN:2168-975X BDT, an open access journal Volume 3 • Issue 3 • 1000128
